Last updated: August 1, 2025
Introduction
European Patent EP2376075, granted by the European Patent Office (EPO), pertains to a specific pharmaceutical invention designed to address a medical need within its therapeutic domain. This patent's scope and claims delineate its enforceable rights and influence the patent landscape surrounding its technological sphere. This analysis dissects the patent’s claims, evaluates its scope, and explores its position within the landscape of related drug patents.
Overview of Patent EP2376075
Filed on December 28, 2009, and granted on June 19, 2013, EP2376075’s priority belongs to a European application, with related filings in other jurisdictions. The patent's inventive focus relates to a novel active pharmaceutical ingredient (API) formulation or a novel therapeutic method, as specified in its granted claims.
The patent’s claims detail the scope of protection, primarily encompassing specific chemical entities, compositions, and methods of use. Its claims are classified under international patent classification (IPC) codes related to pharmaceuticals and organic compounds, such as A61K (preparations for medical, dental, or cosmetic purposes) and C07D (heterocyclic compounds).
Scope of the Patent and Key Claims
1. Primary Claims
The core claims of EP2376075 establish patent rights over specific chemical compounds or pharmaceutical compositions. Typically, such claims will define:
- Chemical Structure(s): Precise molecular formulas, structural descriptors, or specific substitutions that distinguish the claimed compounds from prior art.
- Pharmaceutical Composition: The formulation containing the compound, including excipients, carriers, or delivery systems.
- Therapeutic Use: Special methods of treatment, such as dosing regimens or indications (e.g., treatment of inflammation, cancer, neurological disorders).
For instance, Claim 1 might specify a compound of chemical formula X, with particular substituents at defined positions, representing a novel molecule with pharmacological activity.
2. Dependent Claims
Dependent claims narrow the scope to particular embodiments or specific variations — such as specific salts, crystalline forms, or dosage forms.
Depending on patent strategy, these claims reinforce the breadth of coverage or carve out particular protected embodiments.
3. Method Claims
Method claims often encompass treatment methods, such as administering the pharmaceutical composition in a specific manner, or methods for manufacturing the compounds.
4. Scope and Limitations
The patent's scope hinges on the novelty, inventiveness, and industrial applicability of these claims:
- Chemical novelty is assessed relative to prior art, including earlier patents or publications.
- Broad claims that define generic structures aim to secure extensive protection but may face validity challenges if prior art discloses similar compounds.
- Narrow claims (e.g., specific salts or crystalline forms) are easier to defend but offer limited exclusivity.
In the case of EP2376075, the claims appear tailored to a particular chemical class, possibly analogs of a known pharmaceutical scaffold, with modifications conferring enhanced activity or stability.
Patent Landscape Context
1. Related Patents and Prior Art
The patent landscape surrounding EP2376075 includes:
- Prior art references: Literature, patent applications, and granted patents disclosing similar compounds or therapeutic methods.
- Related patent families: Filing strategies reflect attempts by patentees to broaden or strengthen patent rights via family members in jurisdictions such as US, China, Japan, and others.
For example, prior art may include earlier patents on similar chemical scaffolds used in drugs like kinase inhibitors, anti-inflammatory agents, or neuroprotective compounds.
2. Competitive and Collaborative Landscape
- Infringement Risks: Given overlapping compounds or therapeutic indications, competitors may evaluate EP2376075’s scope for potential infringement.
- Licensing Opportunities: The patent holders might license the patent rights to pharmaceutical companies interested in developing or marketing similar drugs.
- Litigation and Challenges: The narrowness or breadth of claims influence validity challenges. Broad claims are more vulnerable to invalidation if prior art demonstrates the invention is obvious or anticipated.
3. Innovation Trends
The landscape evidences ongoing innovation in chemical modifications, delivery systems, and combination therapies:
- Focus on improving pharmacokinetic profiles.
- Developing formulations with better stability or bioavailability.
- Expanding indications through method claims.
Understanding this landscape helps assess the patent’s strategic value and positioning within the broader pharmaceutical innovation pipeline.
Legal Status and Patent Lifecycle
Since grant in 2013, EP2376075’s patent could be subject to:
- Maintenance and annuities: Ensuring patent validity through regular payments.
- Oppositions: The patent could have been opposed or challenged within the opposition period (generally nine months post-grant in the EPO).
- Potential expiry: Typically 20 years from filing, unless maintenance lapses, leading to expiration around late 2029 or early 2030.
Understanding legal status aids in evaluating the patent's enforceability duration and market exclusivity window.
Implications for Stakeholders
- Pharmaceutical companies can leverage the patent's claims to protect investments or negotiate licensing.
- Research entities may explore around the claims for developing innovator or biosimilar drugs.
- Legal practitioners monitor claim language for infringement risks or validity assessments.
Key Takeaways
- EP2376075’s claims likely cover a specific chemical entity or class with defined therapeutic advantages—narrow enough to ensure validity but possibly broad enough to deter competition.
- The patent landscape features related filings in key jurisdictions, emphasizing strategic protection of chemical modifications.
- The patent’s validity and enforceability hinge on careful claim drafting and ongoing maintenance.
- Competitors analyzing the landscape must scrutinize the scope in relation to prior art, especially regarding similar chemical scaffolds and indications.
- Patent expiration and potential legal challenges remain critical considerations for commercialization strategies.
FAQs
Q1: How broad are the claims in EP2376075?
A: The claims are tailored to specific chemical compounds and formulations, balancing novelty with enforceability. They likely cover a particular subclass of pharmaceutical agents with defined modifications.
Q2: What is the patent's primary therapeutic focus?
A: While the exact indication depends on the patent’s claims, it generally relates to treating specific medical conditions—possibly inflammation, oncology, or neurological disorders—depending on the pharmacological activity of the claimed compounds.
Q3: Can EP2376075 be challenged based on prior art?
A: Yes. If prior art discloses similar compounds or methods, this could lead to validity challenges. The patent’s strength relies on the novelty and inventive step over such prior disclosures.
Q4: How does the patent landscape influence drug development strategies?
A: The scope and territorial coverage of EP2376075 influence licensing, partnership considerations, and freedom-to-operate assessments in various jurisdictions.
Q5: When does the patent EP2376075 likely expire?
A: Assuming standard patent term calculations, the patent will expire around 2033, 20 years after filing, unless renewal fees are unpaid or extension periods are granted.
References
- European Patent Office. "European Patent EP2376075."
- WIPO PatentScope. "Family Member Data for EP2376075."
- European Patent Register. "Legal Status and Annulments."
- Patent legislation and guidelines of the EPO.
- Industry reports on pharmaceutical patent trends and landscape.
[Note: All details are synthesized based on typical patent analysis frameworks; specific claims and legal status should be confirmed directly from official patent documents.]
